| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/24/2013 | EP2582812A1 Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
| 04/24/2013 | EP2582713A1 (11 beta,17 alpha)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one |
| 04/24/2013 | EP2582712A2 Linked purine pterin hppk inhibitors useful as antibacterial agents |
| 04/24/2013 | EP2582709A1 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| 04/24/2013 | EP2582707A2 Polymorphic forms of rifaximin |
| 04/24/2013 | EP2582706A1 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators |
| 04/24/2013 | EP2582705A1 Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors |
| 04/24/2013 | EP2582704A2 Asenapine maleate |
| 04/24/2013 | EP2582703A1 Heteroaryl imidazolone derivatives as jak inhibitors |
| 04/24/2013 | EP2582702A1 Pyrazolopyrimidine kinase inhibitors |
| 04/24/2013 | EP2582701A1 D2 antagonists, methods of synthesis and methods of use |
| 04/24/2013 | EP2582700A2 Respiratory formulations and compounds for use therein |
| 04/24/2013 | EP2582699A1 Substituted triazolopyridines |
| 04/24/2013 | EP2582698A1 Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| 04/24/2013 | EP2582697A1 Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them |
| 04/24/2013 | EP2582694A1 Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorph of these derivatives |
| 04/24/2013 | EP2582692A1 Cyclohexyl-azetidinyl antagonists of ccr2 |
| 04/24/2013 | EP2582689A1 New polymorphic form of imatinib base and preparation of salts thereof |
| 04/24/2013 | EP2582685A1 Process for the preparation of dronedarone |
| 04/24/2013 | EP2582683A1 Treatment of gout and hyperuricemia |
| 04/24/2013 | EP2582682A1 Methods of treating lung disease |
| 04/24/2013 | EP2582681A1 Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| 04/24/2013 | EP2582680A1 Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| 04/24/2013 | EP2582676A1 Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
| 04/24/2013 | EP2582675A1 Compounds for treating proliferative disorders |
| 04/24/2013 | EP2582674A1 Gpr120 receptor agonists and uses thereof |
| 04/24/2013 | EP2582670A1 Piperidinyl compound as a modulator of chemokine receptor activity |
| 04/24/2013 | EP2582668A1 Carboline carboxamide compounds useful as kinase inhibitors |
| 04/24/2013 | EP2582667A1 Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
| 04/24/2013 | EP2582666A2 Aryl substituted indoles and their use as blockers of sodium channels |
| 04/24/2013 | EP2582664A2 Phenylthioacetate compounds, compositions and methods of use |
| 04/24/2013 | EP2582660A1 New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions |
| 04/24/2013 | EP2582432A1 Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection |
| 04/24/2013 | EP2582398A2 Methods of treatment using tlr7 and/or tlr9 inhibitors |
| 04/24/2013 | EP2582396A2 Long lasting drug formulations |
| 04/24/2013 | EP2582393A1 Dose selection of adjuvanted synthetic nanocarriers |
| 04/24/2013 | EP2582384A2 Compositions and methods for treating cancer |
| 04/24/2013 | EP2582376A1 A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof |
| 04/24/2013 | EP2582375A2 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| 04/24/2013 | EP2582374A2 Methods for treating neurological conditions |
| 04/24/2013 | EP2582373A1 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| 04/24/2013 | EP2582372A1 Ranolazine for use for the treatment of pulmonary hypertension |
| 04/24/2013 | EP2582371A1 Methods of treating or preventing estrogen-related diseases |
| 04/24/2013 | EP2582370A1 Compositions containing flavones and anthelmintics |
| 04/24/2013 | EP2582369A1 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| 04/24/2013 | EP2582368A1 Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue |
| 04/24/2013 | EP2582367A2 Methods and systems for modulating hormones and related methods, agents and compositions |
| 04/24/2013 | EP2582366A1 Pharmaceutical combination for the treatment of pain |
| 04/24/2013 | EP2582365A1 Methods and compositions for stimulating reepithelialisation during wound healing |
| 04/24/2013 | EP2582364A2 Transdermal administration of memantine |
| 04/24/2013 | EP2582362A1 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof |
| 04/24/2013 | EP2582361A2 Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| 04/24/2013 | EP2582359A2 Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them |
| 04/24/2013 | EP2582356A1 Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives |
| 04/24/2013 | EP2582355A2 Methods and compositions for promoting hair growth |
| 04/24/2013 | EP2582241A1 Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| 04/24/2013 | EP2582235A2 Oral treatment of digital ischemic lesions |
| 04/24/2013 | EP2301524B1 Inhalable aztreonam without arginine for treatment and prevention of pulmonary bacterial infections |
| 04/24/2013 | EP2111107B1 Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
| 04/24/2013 | CN1935141B Use of descarboethoxyloratadine or its pharmaceutical salts in preparing medicine for treating urticaria |
| 04/24/2013 | CN1922320B Antisense compounds targeted to connexins and methods of use thereof |
| 04/24/2013 | CN1869061B Peptidomimetic protease inhibitors |
| 04/24/2013 | CN1802159B 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
| 04/24/2013 | CN1726915B Nasal cavity drug delivery system and combination of naloxone hydrochloride and preparation method |
| 04/24/2013 | CN1653050B Opioid and opioid-like compounds and uses thereof |
| 04/24/2013 | CN1520303B Turnor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 04/24/2013 | CN103068982A Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| 04/24/2013 | CN103068981A Sirna targeting VEGFA and methods for treatment in VIVO |
| 04/24/2013 | CN103068844A Retinol-modified collagen, method for producing same, and external composition for skin containing same |
| 04/24/2013 | CN103068838A Vaccine against streptococcal infections based on recombinant proteins |
| 04/24/2013 | CN103068830A Inhibitors of arginase and their therapeutic applications |
| 04/24/2013 | CN103068828A Triazolopyrazine derivatives |
| 04/24/2013 | CN103068827A Fused heterocyclic derivatives as s1p modulators |
| 04/24/2013 | CN103068826A New azacyclic compounds |
| 04/24/2013 | CN103068824A Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| 04/24/2013 | CN103068821A 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
| 04/24/2013 | CN103068819A Heterocyclic antiviral compounds |
| 04/24/2013 | CN103068817A Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor |
| 04/24/2013 | CN103068816A Crystal of amide compound |
| 04/24/2013 | CN103068812A Crystalline forms of thalidomide and processes for their preparation |
| 04/24/2013 | CN103068810A Process for the preparation of dronedarone |
| 04/24/2013 | CN103068807A Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound |
| 04/24/2013 | CN103068806A 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| 04/24/2013 | CN103068804A Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators |
| 04/24/2013 | CN103068803A Imidazo[4,5-c]quinolines as DNA-PK inhibitors |
| 04/24/2013 | CN103068802A Compounds for treating proliferative disorders |
| 04/24/2013 | CN103068801A Thioacetate compounds, compositions and methods of use |
| 04/24/2013 | CN103068800A Piperidinyl compound as a modulator of chemokine receptor activity |
| 04/24/2013 | CN103068799A Benzamide derivatives and their use as hsp90 inhibtors |
| 04/24/2013 | CN103068798A Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
| 04/24/2013 | CN103068797A Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application |
| 04/24/2013 | CN103068410A Aqueous gel composition of drug volatilization body |
| 04/24/2013 | CN103068404A Pharmaceutical multimeric particles, and manufacturing method for same |
| 04/24/2013 | CN103068403A Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom |
| 04/24/2013 | CN103068402A Composition for regeneratng normal tissue from fibrotic tissue |
| 04/24/2013 | CN103068396A A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 04/24/2013 | CN103068395A Therapeutic agent for disease |
| 04/24/2013 | CN103068394A Topical treatments for pain |
| 04/24/2013 | CN103068393A Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase |
| 04/24/2013 | CN103068392A Polymorphs of alogliptin benzoate |